Literature DB >> 12039034

Alternative splicing, expression, and gene structure of the septin-like putative proto-oncogene Sint1.

Annette Balle Sørensen1, Søren Warming, Ernst Martin Füchtbauer, Finn Skou Pedersen.   

Abstract

Sint1 (sept9), a murine gene of the septin family, was previously isolated as a putative proto-oncogene involved in T-cell lymphomagenesis. We now present its genomic structure and report on nine exons shared by all identified variants and at least four alternatively spliced 5' exons. Northern blot analyses using a Sint1 cDNA probe showed in almost all examined tissues two predominant transcripts of 3 and 4 kb. Exon-specific expression analyses assigned one of the 5' exons to the 4 kb transcript, while the other 5' exons seem to represent novel, tissue-specific, weakly expressed transcripts of different sizes, and none of them appear to hybridize to the major 3 kb transcript. Whole-mount in situ hybridization on post-implantation embryos revealed several areas strongly expressing Sint1, including neural crest cells, cephalic mesenchyme, and mesenchymal cells in the developing limb. A clustering of proviruses in four independent retrovirally induced tumors point to a region of about 3 kb around the most upstream exon as important for proviral deregulation of Sint1.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12039034     DOI: 10.1016/s0378-1119(02)00406-7

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  8 in total

1.  The mammalian septin MSF localizes with microtubules and is required for completion of cytokinesis.

Authors:  Mark C Surka; Christopher W Tsang; William S Trimble
Journal:  Mol Biol Cell       Date:  2002-10       Impact factor: 4.138

2.  Discovery of transcription factors and other candidate regulators of neural crest development.

Authors:  Meghan S Adams; Laura S Gammill; Marianne Bronner-Fraser
Journal:  Dev Dyn       Date:  2008-04       Impact factor: 3.780

3.  Disruption of Sept6, a fusion partner gene of MLL, does not affect ontogeny, leukemogenesis induced by MLL-SEPT6, or phenotype induced by the loss of Sept4.

Authors:  Ryoichi Ono; Masafumi Ihara; Hideaki Nakajima; Katsutoshi Ozaki; Yuki Kataoka-Fujiwara; Tomohiko Taki; Koh-Ichi Nagata; Masaki Inagaki; Nobuaki Yoshida; Toshio Kitamura; Yasuhide Hayashi; Makoto Kinoshita; Tetsuya Nosaka
Journal:  Mol Cell Biol       Date:  2005-12       Impact factor: 4.272

Review 4.  Applying circulating tumor DNA methylation in the diagnosis of lung cancer.

Authors:  Lei Li; Kai Fu; Wenyu Zhou; Michael Snyder
Journal:  Precis Clin Med       Date:  2019-03-15

5.  A variant-type MLL/SEPT9 fusion transcript in adult de novo acute monocytic leukemia (M5b) with t(11;17)(q23;q25).

Authors:  Tetsuya Kurosu; Kana Tsuji; Manabu Ohki; Tohru Miki; Masahide Yamamoto; Kazuhiko Kakihana; Takatoshi Koyama; Shuichi Taniguchi; Osamu Miura
Journal:  Int J Hematol       Date:  2008-07-19       Impact factor: 2.490

6.  Whole-transcriptome splicing profiling of E7.5 mouse primary germ layers reveals frequent alternative promoter usage during mouse early embryogenesis.

Authors:  Xukun Lu; Zhen-Ao Zhao; Xiaoqing Wang; Xiaoxin Zhang; Yanhua Zhai; Wenbo Deng; Zhaohong Yi; Lei Li
Journal:  Biol Open       Date:  2018-03-28       Impact factor: 2.422

7.  Septins are critical regulators of osteoclastic bone resorption.

Authors:  Anaïs M J Møller; Ernst-Martin Füchtbauer; Annemarie Brüel; Thomas L Andersen; Xenia G Borggaard; Nathan J Pavlos; Jesper S Thomsen; Finn S Pedersen; Jean-Marie Delaisse; Kent Søe
Journal:  Sci Rep       Date:  2018-08-29       Impact factor: 4.379

8.  Septin 9 isoforms promote tumorigenesis in mammary epithelial cells by increasing migration and ECM degradation through metalloproteinase secretion at focal adhesions.

Authors:  Jenna Marcus; Michal Bejerano-Sagie; Nicole Patterson; Susmita Bagchi; Vladislav V Verkhusha; Diana Connolly; Gary L Goldberg; Aaron Golden; Ved P Sharma; John Condeelis; Cristina Montagna
Journal:  Oncogene       Date:  2019-07-08       Impact factor: 9.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.